An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics
- PMID: 1679338
- DOI: 10.1007/BF01244973
An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics
Abstract
Eleven schizophrenics (7 females) displaying an acute psychotic episode received the partial dopamine agonist terguride in doses up to 2 mg per day. Improvement in terms of positive symptoms reduction was observed in two cases only. In contrast, in a previous clinical trial targeted at negative schizophrenic symptoms, the majority of the patients appeared to have benefited from terguride application.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical